Ajinomoto Cambrooke, Inc.

About Ajinomoto Cambrooke, Inc.

Ajinomoto Cambrooke, Inc., formerly Cambrooke Therapeutics, Inc. (expansion of Cambrooke Foods), was founded in 2000 by Lynn and David Paolella, the parents of two children diagnosed with a rare disease called phenylketonuria (PKU). PKU is one of the few genetic diseases managed almost entirely with nutritional intervention. The Paolellas’ goal in forming Cambrooke was simple: to develop improved nutritional therapeutic options for those with serious medical disorders. Today, Cambrooke produces medical formulas and foods for the management of a variety of medical conditions, and we are continually innovating new nutritional options targeted at a wide array of diseases. Cambrooke was the first medical foods company to launch a natural intact protein for the dietary management of phenylketonuria called Glytactin (modified glycomacropeptide). Cambrooke collaborates with academia and industry partners to transform early phase development projects in therapeutic nutrition into viable commercial products. Cambrooke employs scientific experts in the development, manufacturing, and commercialization of nutritional therapeutics for patients with rare diseases. Cambrooke’s products are supported by clinical evidence for the nutritional management of medical needs before they are selected for commercialization. Cambrooke believes that both large and small patient populations are important when it comes to complex nutritional requirements.